{"description":"Documents matching 'glutathione'","count":186,"total_pages":10,"next_page_url":"https://www.federalregister.gov/api/v1/documents?conditions%5Bterm%5D=glutathione&format=json&page=2","results":[{"title":"Government Owned Inventions Available for License: Establishment and Characterization of the A1847 Human Ovarian Carcinoma Line","type":"Notice","abstract":"The National Cancer Institute (NCI) seeks licensees for a tumorigenic cell line, A1847, from a patient with metastatic ovarian cancer. As a BRCA1 deficient cell line, it serves as a model to researchers studying cell cycle regulation, tumor suppression and effective drugs aiding in repair of DNA damage.","document_number":"2026-12070","html_url":"https://www.federalregister.gov/documents/2026/06/16/2026-12070/government-owned-inventions-available-for-license-establishment-and-characterization-of-the-a1847","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-06-16/pdf/2026-12070.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-12070.pdf?1781527514","publication_date":"2026-06-16","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"excerpts":"interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer. (PMID \n 23056589 \n ).\n \n \n • Godwin, A.K., et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of <span class=\"match\">glutathione</span> synthesis. (PMID \n 1348364. \n )\n \n \n Potential Commercial Applications: \n \n • Tool to conduct preclinical proof-of-concept studies required for commercial development of anti-cancer agents and targeted therapies in ovarian cancer. \n • Research model to investigate epithelial"},{"title":"Foreign-Trade Zone (FTZ) 200, Notification of Proposed Production Activity; Shiseido America, Inc.; (Cosmetic and Beauty Products); East Windsor and Cranbury, New Jersey","type":"Notice","abstract":null,"document_number":"2026-10414","html_url":"https://www.federalregister.gov/documents/2026/05/26/2026-10414/foreign-trade-zone-ftz-200-notification-of-proposed-production-activity-shiseido-america-inc","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-26/pdf/2026-10414.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-10414.pdf?1779453918","publication_date":"2026-05-26","agencies":[{"raw_name":"DEPARTMENT OF COMMERCE","name":"Commerce Department","id":54,"url":"https://www.federalregister.gov/agencies/commerce-department","json_url":"https://www.federalregister.gov/api/v1/agencies/54","parent_id":null,"slug":"commerce-department"},{"raw_name":"Foreign-Trade Zones Board","name":"Foreign-Trade Zones Board","id":208,"url":"https://www.federalregister.gov/agencies/foreign-trade-zones-board","json_url":"https://www.federalregister.gov/api/v1/agencies/208","parent_id":54,"slug":"foreign-trade-zones-board"}],"excerpts":"methylparaben; ethylhexyl methoxycinnamate; phytic acid; dicaprylyl carbonate; triethanolamine; aminomethyl propanol; glutamic acid; tripeptide-1; lecithin; betaine; dibutyl lauroyl glutamide; phytosteryl/octyldodecyl lauroyl glutamate (mixture); creatine; octocrylene; <span class=\"match\">glutathione</span>; trisiloxane; gluconolactone; ascorbyl tetraisopalmitate; epigallocatechin gallate; allantoin; carnosine; piperidinepropionic acid; ectoine; sodium pca; hydroxyproline; adenosine; thioctic acid; panthenol; tocopheryl acetate; niacinamide; copper tripeptide-1; glucosylrutin;"},{"title":"Propylene Oxide; Pesticide Tolerances","type":"Rule","abstract":"This regulation establishes tolerances for residues of propylene oxide (PPO) in or on sesame, seed; turmeric, roots, dried; ginger, dried; pepper, bell, dried; and pepper, nonbell, dried. ABERCO, Inc., a Balchem Company, submitted a petition to EPA requesting that EPA establish a maximum permissible level for residues of this pesticide in or on the identified commodities.","document_number":"2026-10711","html_url":"https://www.federalregister.gov/documents/2026/05/29/2026-10711/propylene-oxide-pesticide-tolerances","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-29/pdf/2026-10711.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-10711.pdf?1779972317","publication_date":"2026-05-29","agencies":[{"raw_name":"ENVIRONMENTAL PROTECTION AGENCY","name":"Environmental Protection Agency","id":145,"url":"https://www.federalregister.gov/agencies/environmental-protection-agency","json_url":"https://www.federalregister.gov/api/v1/agencies/145","parent_id":null,"slug":"environmental-protection-agency"}],"excerpts":"systemically via those routes. Hydrolysis of PPO may occur spontaneously in the acidic environment of the stomach. Under \n in vitro \n conditions similar to the stomach environment, PPO hydrolysis is fast (half-life of 1 minute) and yields propylene glycol. Conjugation of PPO to <span class=\"match\">glutathione</span> (GSH), and alkylation to DNA or proteins can also occur, especially at the portal of entry. Chronic oral gavage dosing induced forestomach lesions in rats; however, this effect is not relevant for risk assessment because humans do not have a forestomach or any similar tissues"},{"title":"Safety Standard for Toys: Requirements for Water Beads","type":"Rule","abstract":"Section 106(a) of the Consumer Product Safety Improvement Act of 2008 (CPSIA) mandates that ASTM F963 shall be a mandatory toy safety standard. This safety standard sets forth requirements for water bead toys and toys that contain water beads. Under this statutory authority, the U.S. Consumer Product Safety Commission (CPSC or Commission) is issuing a safety standard for water bead toys and toys that contain water beads.","document_number":"2025-22643","html_url":"https://www.federalregister.gov/documents/2025/12/12/2025-22643/safety-standard-for-toys-requirements-for-water-beads","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-12-12/pdf/2025-22643.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-22643.pdf?1765460714","publication_date":"2025-12-12","agencies":[{"raw_name":"CONSUMER PRODUCT SAFETY COMMISSION","name":"Consumer Product Safety Commission","id":84,"url":"https://www.federalregister.gov/agencies/consumer-product-safety-commission","json_url":"https://www.federalregister.gov/api/v1/agencies/84","parent_id":null,"slug":"consumer-product-safety-commission"}],"excerpts":"ATSDR's exposure limit is based on rodent studies, and that acrylamide metabolism differs significantly between rodents and humans. Rodents metabolize acrylamide largely via the CYP 2E1 oxidation pathway to glycidamide, and humans metabolize acrylamide via conjugation with <span class=\"match\">glutathione</span> to a much greater extent. \n 4. The commenters both explain that acrylamide is also known to occur in many foods at levels that can create higher exposures than the proposed acrylamide limit in water beads. Both commenters provided several examples of acrylamide in food"},{"title":"Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments","type":"Notice","abstract":"The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Pharmacy Compounding Advisory Committee. The general function of the committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.","document_number":"2022-09797","html_url":"https://www.federalregister.gov/documents/2022/05/06/2022-09797/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2022-05-06/pdf/2022-09797.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2022-09797.pdf?1651754744","publication_date":"2022-05-06","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"heard, viewed, captioned, and recorded through an online teleconferencing platform. The committee will discuss the following four bulk drug substances nominated for inclusion on the 503A Bulks List: Ammonium tetrathiomolybdate, enclomiphene citrate, ferric subsulfate, and <span class=\"match\">glutathione</span>. The chart below identifies the use(s) FDA reviewed for each of the four bulk drug substances being discussed at this advisory committee meeting. The nominators of these substances or another interested party will be invited to make a short presentation supporting the nomination"},{"title":"Medicare Program; Proposed Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2024 Rates; Quality Programs and Medicare Promoting Interoperability Program Requirements for Eligible Hospitals and Critical Access Hospitals; Rural Emergency Hospital and Physician-Owned Hospital Requirements; and Provider and Supplier Disclosure of Ownership","type":"Proposed Rule","abstract":"This proposed rule would: revise the Medicare hospital inpatient prospective payment systems (IPPS) for operating and capital- related costs of acute care hospitals; make changes relating to Medicare graduate medical education (GME) for teaching hospitals; update the payment policies and the annual payment rates for the Medicare prospective payment system (PPS) for inpatient hospital services provided by long-term care hospitals (LTCHs); and make other policy-related changes.","document_number":"2023-07389","html_url":"https://www.federalregister.gov/documents/2023/05/01/2023-07389/medicare-program-proposed-hospital-inpatient-prospective-payment-systems-for-acute-care-hospitals","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2023-05-01/pdf/2023-07389.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2023-07389.pdf?1681157722","publication_date":"2023-05-01","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"about a week, GALA `as is' is rendered not suitable for distribution \n \n and commercialization.\n 40 \n \n According to the applicant, GALA's shelf-life was primarily driven by chemical instability of L-<span class=\"match\">glutathione</span> and ascorbic acid, which were observed to be rapidly and substantially lost to oxidation within a few days of GALA compounding. L-<span class=\"match\">glutathione</span> and ascorbic acid are antioxidant components that play key roles in protecting vein grafts against ischemic injury and in particular oxidative damage, which is a primary driver of ischemic injury. The"},{"title":"Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2026 Rates; Requirements for Quality Programs; and Other Policy Changes","type":"Proposed Rule","abstract":"This proposed rule would revise the Medicare hospital inpatient prospective payment systems (IPPS) for operating and capital- related costs of acute care hospitals; make changes relating to Medicare graduate medical education (GME) for teaching hospitals; update the payment policies and the annual payment rates for the Medicare prospective payment system (PPS) for inpatient hospital services provided by long-term care hospitals (LTCHs); update and make changes to requirements for certain quality programs; and make other policy-related changes.","document_number":"2025-06271","html_url":"https://www.federalregister.gov/documents/2025/04/30/2025-06271/medicare-program-hospital-inpatient-prospective-payment-systems-for-acute-care-hospitals-and-the","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-04-30/pdf/2025-06271.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-06271.pdf?1744402510","publication_date":"2025-04-30","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"solutions do not prevent ischemic or oxidative damage, as they merely maintain pH balance.\n 62 \n \n The applicant asserted that, in contrast, DuraGraft® offers a unique mechanism by creating a reducing environment to prevent oxidative damage during ischemic storage, using L-<span class=\"match\">glutathione</span> and L-Ascorbic acid, which has been associated with reduced graft wall thickening and a significant three-year mortality benefit, and therefore, in no way should these liquids be compared to or considered similar to DuraGraft®.\n \n \n \n 58 \n  Alexander, J.H., Hafley, G.,"},{"title":"Medicare and Medicaid Programs and the Children's Health Insurance Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2025 Rates; Quality Programs Requirements; and Other Policy Changes","type":"Rule","abstract":"This final rule revises the Medicare hospital inpatient prospective payment systems (IPPS) for operating and capital-related costs of acute care hospitals; makes changes relating to Medicare graduate medical education (GME) for teaching hospitals; updates the payment policies and the annual payment rates for the Medicare prospective payment system (PPS) for inpatient hospital services provided by long-term care hospitals (LTCHs); and makes other policy- related changes.","document_number":"2024-17021","html_url":"https://www.federalregister.gov/documents/2024/08/28/2024-17021/medicare-and-medicaid-programs-and-the-childrens-health-insurance-program-hospital-inpatient","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-08-28/pdf/2024-17021.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-17021.pdf?1722960072","publication_date":"2024-08-28","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"structural and functional integrity of vascular conduits. The applicant asserted that Duragraft®'s primary function is to provide a reducing environment for vascular grafts to prevent oxidative damage which occurs during ischemic storage of grafts, using a combination of L-<span class=\"match\">glutathione</span> and L-Ascorbic acid that is manufactured in such a way as to preserve these molecules in their reduced state. The applicant concluded that, based upon composition, the stated mechanism of action, and preclinical evidence showing maintenance of the graft's structural and"},{"title":"Food Additive Regulations; Synthetic Flavoring Agents and Adjuvants","type":"Rule","abstract":"The Food and Drug Administration (FDA, the Agency, or we) is partially granting a petition submitted by the Breast Cancer Fund (now known as the Breast Cancer Prevention Partners), Center for Environmental Health, Center for Food Safety, Center for Science in the Public Interest, Consumers Union, Environmental Defense Fund, Environmental Working Group, Improving Kids' Environment, Natural Resources Defense Council, WE ACT for Environmental Justice, and Mr. James Huff, by amending the food additive regulations to no longer authorize the use of benzophenone, ethyl acrylate, eugenyl methyl ether, myrcene, pulegone, and pyridine as synthetic flavoring substances for use in food. We are taking this action because, despite FDA's scientific analysis and determination that these substances do not pose a risk to public health under the conditions of their intended use, the petitioners provided data demonstrating that these additives induce cancer in laboratory animals, and, as a result of this finding in animals, FDA cannot as a matter of law maintain the listing of these synthetic flavoring substances in the food additive regulations. Because of evidence that benzophenone causes cancer in animals, FDA also is amending the food additive regulations to no longer provide for the use of benzophenone as a plasticizer in rubber articles intended for repeated use in contact with food. FDA is denying as moot the portions of the petition proposing that the food additive regulations be amended to no longer authorize the use of styrene as a synthetic flavoring substance because this use has been permanently and completely abandoned. In addition, FDA is declining to act on the petitioners' request to issue a regulation to prohibit the use of these synthetic flavoring substances in food because that issue is not the proper subject of a food additive petition.","document_number":"2018-21807","html_url":"https://www.federalregister.gov/documents/2018/10/09/2018-21807/food-additive-regulations-synthetic-flavoring-agents-and-adjuvants","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2018-10-09/pdf/2018-21807.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2018-21807.pdf?1538743528","publication_date":"2018-10-09","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"formation and <span class=\"match\">glutathione</span> depletion have been postulated as potential MOAs of pulegone via menthofuran formation, which could cause cytotoxicity and chronic cell proliferation, and ultimately lead to liver neoplasms. In vivo and in vitro studies showed an association between hepatocellular damage caused by menthofuran and its metabolic activation to γ-ketoenal, 8-pulegone aldehyde and covalent binding to target organ proteins. Further, p-cresol, another pulegone metabolite produced in rodents given high doses of pulegone, depletes <span class=\"match\">glutathione</span> levels."},{"title":"Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Proposed Policy Changes and Fiscal Year 2020 Rates; Proposed Quality Reporting Requirements for Specific Providers; Medicare and Medicaid Promoting Interoperability Programs Proposed Requirements for Eligible Hospitals and Critical Access Hospitals","type":"Proposed Rule","abstract":"We are proposing to revise the Medicare hospital inpatient prospective payment systems (IPPS) for operating and capital-related costs of acute care hospitals to implement changes arising from our continuing experience with these systems for FY 2020 and to implement certain recent legislation. We also are proposing to make changes relating to Medicare graduate medical education (GME) for teaching hospitals and payments to critical access hospital (CAHs). In addition, we are proposing to provide the market basket update that would apply to the rate-of-increase limits for certain hospitals excluded from the IPPS that are paid on a reasonable cost basis, subject to these limits for FY 2020. We are proposing to update the payment policies and the annual payment rates for the Medicare prospective payment system (PPS) for inpatient hospital services provided by long-term care hospitals (LTCHs) for FY 2020. In this proposed rule, we are including proposals to address wage index disparities between high and low wage index hospitals; to provide for an alternative IPPS new technology add-on payment pathway for certain transformative new devices; and to revise the calculation of the IPPS new technology add-on payment. In addition, we are requesting public comments on the substantial clinical improvement criterion used for evaluating applications for both the IPPS new technology add-on payment and the OPPS transitional pass- through payment for devices, and we discuss potential revisions that we are considering adopting as final policies related to the substantial clinical improvement criterion for applications received beginning in FY 2020 for IPPS (that is, for FY 2021 and later new technology add-on payments) and beginning in CY 2020 for the OPPS. We are proposing to establish new requirements or revise existing requirements for quality reporting by specific Medicare providers (acute care hospitals, PPS-exempt cancer hospitals, and LTCHs). We also are proposing to establish new requirements and revise existing requirements for eligible hospitals and critical access hospitals (CAHs) participating in the Medicare and Medicaid Promoting Interoperability Programs. We are proposing to update policies for the Hospital Value-Based Purchasing (VBP) Program, the Hospital Readmissions Reduction Program, and the Hospital-Acquired Condition (HAC) Reduction Program.","document_number":"2019-08330","html_url":"https://www.federalregister.gov/documents/2019/05/03/2019-08330/medicare-program-hospital-inpatient-prospective-payment-systems-for-acute-care-hospitals-and-the","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2019-05-03/pdf/2019-08330.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2019-08330.pdf?1556050531","publication_date":"2019-05-03","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"combines free radical scavengers and antioxidants (<span class=\"match\">glutathione</span>, ascorbic acid) and nitric oxide synthase substrate (L-arginine) providing a favorable environment and cellular support during ex vivo storage.\n 139 \n \n The same study also indicated that these three ingredients were chosen because of their putative effect on endothelial cell function and that their use may act synergistically to enhance the cell preservation properties of the solution. The authors of the study asserted that <span class=\"match\">glutathione</span> increases L-arginine transport in endothelial cells"},{"title":"Medical Devices; Exemptions From Premarket Notification: Class II Devices","type":"Notice","abstract":"The Food and Drug Administration (FDA or Agency) is announcing a list of class II devices that the Agency has determined based on established factors to no longer require premarket notification to provide reasonable assurance of safety and effectiveness, subject to certain limitations. FDA is publishing this notice of that determination in accordance with procedures established by the 21st Century Cures Act. This notice represents FDA's final determination with respect to the list of class II devices proposed in a March 14, 2017, Federal Register document. The exemptions in this notice will decrease regulatory burdens on the medical device industry and will eliminate private costs and expenditures required to comply with certain Federal regulations.","document_number":"2017-14453","html_url":"https://www.federalregister.gov/documents/2017/07/11/2017-14453/medical-devices-exemptions-from-premarket-notification-class-ii-devices","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2017-07-11/pdf/2017-14453.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2017-14453.pdf?1499690754","publication_date":"2017-07-11","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"7275 \n Test, Euglobulin Lysis \n JBO \n \n \n 864.7300 \n Fibrin Monomer Paracoagulation \n JBN \n \n \n 864.7340 \n Fibrinogen Standard \n GFX \n \n \n 864.7340 \n Plasma, Fibrinogen Control \n GIL \n \n \n 864.7375 \n <span class=\"match\">Glutathione</span>, Red-Cell \n GII \n \n \n 864.7375 \n Fluorescence, Visual Observation (Qual., U.V.), <span class=\"match\">Glutathione</span> Reductase \n JMH \n \n \n 864.7375 \n Assay, <span class=\"match\">Glutathione</span> Reductase \n KQF \n \n \n 864.7415 \n Control, Hemoglobin, Abnormal \n JCM \n \n \n 864.7455 \n Stain, Fetal Hemoglobin \n GHQ \n \n \n 864.7500 \n Acid Hematin \n GGF \n \n \n 864.7720 \n Test, Prothrombin Consumption"},{"title":"Prospective Grant of Start-up Exclusive Evaluation Option Patent License: “The Development and Use of Diazeniumdiolated and Hybrid Diazeniumdiolated Compounds for the Treatment of Ovarian Cancer in Humans”","type":"Notice","abstract":"The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-up Exclusive Evaluation Option License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Tar Meta Biosciences, Inc. (\"TarMeta\") located in King of Prussia, PA, USA.","document_number":"2017-06545","html_url":"https://www.federalregister.gov/documents/2017/04/04/2017-06545/prospective-grant-of-start-up-exclusive-evaluation-option-patent-license-the-development-and-use-of","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2017-04-04/pdf/2017-06545.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2017-06545.pdf?1491223524","publication_date":"2017-04-04","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"excerpts":"cells to produce synergistic effects, whether alone or as an adjuvant for other therapies. The hybrid prodrug is expected to enhance cytotoxicity by creating DNA damage with NO and preventing its repair with the PARP inhibitor. The prodrug and the hybrid are activated by <span class=\"match\">glutathione</span> S-transferase and are predicted to be effective in cancers with reactive oxygen species (ROS), both of which are elevated in many cancers. In addition, the prodrug and hybrid may have synergy with therapeutics (such as proteasome inhibitor bortezomib and doxorubicin) which"},{"title":"Medical Devices; Exemptions From Premarket Notification: Class II Devices; Request for Comments","type":"Notice","abstract":"The Food and Drug Administration (FDA or Agency) has identified a list of class II devices that, when finalized, will be exempt from premarket notification requirements, subject to certain limitations. FDA is publishing this notice of that determination and requesting public comment in accordance with procedures established by the 21st Century Cures Act. This notice does not represent FDA's final determination with respect to the class II devices included in this document. FDA will review any comments submitted within the 60-day comment period and will consider whether the list of class II devices should be modified prior to publication of its final determination in the Federal Register.","document_number":"2017-04938","html_url":"https://www.federalregister.gov/documents/2017/03/14/2017-04938/medical-devices-exemptions-from-premarket-notification-class-ii-devices-request-for-comments","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2017-03-14/pdf/2017-04938.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2017-04938.pdf?1489409137","publication_date":"2017-03-14","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Euglobulin Lysis \n JBO \n \n \n \n 864.7300 \n Fibrin Monomer Paracoagulation \n JBN \n \n \n \n 864.7340 \n Fibrinogen Standard \n GFX \n \n \n \n 864.7340 \n Plasma, Fibrinogen Control \n GIL \n \n \n \n 864.7375 \n <span class=\"match\">Glutathione</span>, Red-Cell \n GII \n \n \n \n 864.7375 \n Fluorescence, Visual Observation (Qual., U.V.), <span class=\"match\">Glutathione</span> Reductase \n JMH \n \n \n \n 864.7375 \n Assay, <span class=\"match\">Glutathione</span> Reductase \n KQF \n \n \n \n 864.7415 \n Control, Hemoglobin, Abnormal \n JCM \n \n \n \n 864.7455 \n Stain, Fetal Hemoglobin \n GHQ \n \n \n \n 864.7500 \n Acid Hematin \n GGF \n \n \n \n 864.7720 \n Test, Prothrombin"},{"title":"National Primary Drinking Water Regulations; Announcement of the Results of EPA's Review of Existing Drinking Water Standards and Request for Public Comment and/or Information on Related Issues","type":"Proposed Rule","abstract":"The Safe Drinking Water Act (SDWA) requires the U.S. Environmental Protection Agency (EPA) to conduct a review every six years of existing national primary drinking water regulations (NPDWRs) and determine which, if any, need to be revised. The purpose of the review, called the Six-Year Review, is to evaluate current information for regulated contaminants to determine if there is new information on health effects, treatment technologies, analytical methods, occurrence and exposure, implementation and/or other factors that provides a health or technical basis to support a regulatory revision that will improve or strengthen public health protection. EPA has completed a detailed review of 76 NPDWRs and at this time has determined that eight NPDWRs are candidates for regulatory revision. The eight NPDWRs are included in the Stage 1 and the Stage 2 Disinfectants and Disinfection Byproducts Rules, the Surface Water Treatment Rule, the Interim Enhanced Surface Water Treatment Rule and the Long Term 1 Enhanced Surface Water Treatment Rule. EPA requests comments on the eight NPDWRs identified as candidates for revision and will consider comments and data as it proceeds with determining whether further action is needed. In addition, as part of this Six-Year Review, EPA identified 12 other NPDWRs that were or continue to be addressed in recently completed, ongoing or pending regulatory actions. EPA thus excluded those 12 NPDWRs from detailed review. This document is not a final regulatory decision, but rather the initiation of a process that will involve more detailed analyses of factors relevant to deciding whether a rulemaking to revise an NPDWR should be initiated.","document_number":"2016-31262","html_url":"https://www.federalregister.gov/documents/2017/01/11/2016-31262/national-primary-drinking-water-regulations-announcement-of-the-results-of-epas-review-of-existing","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2017-01-11/pdf/2016-31262.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2016-31262.pdf?1484055927","publication_date":"2017-01-11","agencies":[{"raw_name":"ENVIRONMENTAL PROTECTION AGENCY","name":"Environmental Protection Agency","id":145,"url":"https://www.federalregister.gov/agencies/environmental-protection-agency","json_url":"https://www.federalregister.gov/api/v1/agencies/145","parent_id":null,"slug":"environmental-protection-agency"}],"excerpts":"and roadmap for research. Mutation Research. 636(1-3): 178-242. \n \n Ross, M.K. and R.A. Pegram. 2003. <span class=\"match\">Glutathione</span> transferase theta 1-1-dependent metabolism of the water disinfection byproduct \n \n bromodichloromethane. Chemical Research in Toxicology. 16(2): 216-226.\n \n Ross, M.K. and R.A. Pegram. 2004. In vitro biotransformation and genotoxicity of the drinking water disinfection byproduct bromodichloromethane: DNA binding mediated by <span class=\"match\">glutathione</span> transferase theta 1-1. Toxicology and Applied Pharmacology. 195(2): 166-181. \n Saad, B, W.T. Wai, M.S"},{"title":"Trichloroethylene (TCE); Regulation of Use in Vapor Degreasing Under TSCA Section 6(a)","type":"Proposed Rule","abstract":"Trichloroethylene (TCE) is a volatile organic compound widely used in industrial and commercial processes and has some limited uses in consumer and commercial products. EPA identified significant health risks associated with TCE use in vapor degreasing and EPA's proposed determination is that these risks are unreasonable risks. To address these unreasonable risks, EPA is proposing under section 6 of the Toxic Substances Control Act (TSCA) to prohibit the manufacture (including import), processing, and distribution in commerce of TCE for use in vapor degreasing; to prohibit commercial use of TCE in vapor degreasing; to require manufacturers, processors, and distributors, except for retailers of TCE for any use, to provide downstream notification of these prohibitions throughout the supply chain; and to require limited recordkeeping.","document_number":"2017-01229","html_url":"https://www.federalregister.gov/documents/2017/01/19/2017-01229/trichloroethylene-tce-regulation-of-use-in-vapor-degreasing-under-tsca-section-6a","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2017-01-19/pdf/2017-01229.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2017-01229.pdf?1484747239","publication_date":"2017-01-19","agencies":[{"raw_name":"ENVIRONMENTAL PROTECTION AGENCY","name":"Environmental Protection Agency","id":145,"url":"https://www.federalregister.gov/agencies/environmental-protection-agency","json_url":"https://www.federalregister.gov/api/v1/agencies/145","parent_id":null,"slug":"environmental-protection-agency"}],"excerpts":"metabolites derived from <span class=\"match\">glutathione</span> conjugation (in particular DCVC) can be systemically delivered or formed in the kidney. Moreover, DCVC‐treated animals showed the same type of kidney damage as those treated with TCE (Ref. 2). The toxicokinetic data and the genotoxicity of DCVC further suggest that a mutagenic mode of action is involved in TCE‐induced kidney tumors, although cytotoxicity followed by compensatory cellular proliferation cannot be ruled out. As for the mutagenic mode of action, both genetic polymorphisms (<span class=\"match\">Glutathione</span> transferase (GST)"},{"title":"Trichloroethylene; Regulation of Certain Uses Under TSCA § 6(a)","type":"Proposed Rule","abstract":"Trichloroethylene (TCE) is a volatile organic compound widely used in industrial and commercial processes and has some limited uses in consumer and commercial products. EPA identified significant health risks associated with TCE use in aerosol degreasing and for spot cleaning in dry cleaning facilities. EPA has preliminarily determined that these risks are unreasonable risks. To address these unreasonable risks, EPA is proposing under section 6 of the Toxic Substances Control Act (TSCA) to prohibit the manufacture, processing, and distribution in commerce of TCE for use in aerosol degreasing and for use in spot cleaning in dry cleaning facilities; to prohibit commercial use of TCE for aerosol degreasing and for spot cleaning in dry cleaning facilities; to require manufacturers, processors, and distributors, except for retailers of TCE for any use, to provide downstream notification of these prohibitions throughout the supply chain; and to require limited recordkeeping.","document_number":"2016-30063","html_url":"https://www.federalregister.gov/documents/2016/12/16/2016-30063/trichloroethylene-regulation-of-certain-uses-under-tsca--6a","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2016-12-16/pdf/2016-30063.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2016-30063.pdf?1481809535","publication_date":"2016-12-16","agencies":[{"raw_name":"ENVIRONMENTAL PROTECTION AGENCY","name":"Environmental Protection Agency","id":145,"url":"https://www.federalregister.gov/agencies/environmental-protection-agency","json_url":"https://www.federalregister.gov/api/v1/agencies/145","parent_id":null,"slug":"environmental-protection-agency"}],"excerpts":"metabolites derived from <span class=\"match\">glutathione</span> conjugation (in particular DCVC) can be systemically delivered or formed in the kidney. Moreover, DCVC-treated animals showed the same type of kidney damage as those treated with TCE (Ref. 1). The toxicokinetic data and the genotoxicity of DCVC further suggest that a mutagenic mode of action is involved in TCE-induced kidney tumors, although cytotoxicity followed by compensatory cellular proliferation cannot be ruled out. As for the mutagenic mode of action, both genetic polymorphisms (<span class=\"match\">Glutathione</span> transferase (GST)"},{"title":"Addition of Hexabromocyclododecane (HBCD) Category; Community Right-to-Know Toxic Chemical Release Reporting","type":"Proposed Rule","abstract":"EPA is proposing to add a hexabromocyclododecane (HBCD) category to the list of toxic chemicals subject to reporting under section 313 of the Emergency Planning and Community Right-to-Know Act (EPCRA) and section 6607 of the Pollution Prevention Act (PPA). EPA is proposing to add this chemical category to the EPCRA section 313 list because EPA believes HBCD meets the EPCRA section 313(d)(2)(B) and (C) toxicity criteria. Specifically, EPA believes that HBCD can reasonably be anticipated to cause developmental and reproductive effects in humans and is highly toxic to aquatic and terrestrial organisms. In addition, based on the available bioaccumulation and persistence data, EPA believes that HBCD should be classified as a persistent, bioaccumulative, and toxic (PBT) chemical and assigned a 100-pound reporting threshold. Based on a review of the available production and use information, members of the HBCD category are expected to be manufactured, processed, or otherwise used in quantities that would exceed a 100-pound EPCRA section 313 reporting threshold.","document_number":"2016-12464","html_url":"https://www.federalregister.gov/documents/2016/06/02/2016-12464/addition-of-hexabromocyclododecane-hbcd-category-community-right-to-know-toxic-chemical-release","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2016-06-02/pdf/2016-12464.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2016-12464.pdf?1464785135","publication_date":"2016-06-02","agencies":[{"raw_name":"ENVIRONMENTAL PROTECTION AGENCY","name":"Environmental Protection Agency","id":145,"url":"https://www.federalregister.gov/agencies/environmental-protection-agency","json_url":"https://www.federalregister.gov/api/v1/agencies/145","parent_id":null,"slug":"environmental-protection-agency"}],"excerpts":"indicative of antioxidant defenses and oxidative stress after 1, 3, 6, 10, and 15 days of exposure to low nominal concentrations of HBCD ranging from 0.000086 to 0.0086 mg/L in the clam \n Venerupis philippinarum. \n Increases in ethyoxyresorufin-o-deethylase (EROD) activity, <span class=\"match\">glutathione</span> (GSH) content, and DNA damage were observed in clams exposed to 0.00086 mg/L, while increased lipid peroxidation (LPO) was observed at 0.0086 mg/L. These same effects were observed at lower concentrations as the length of exposure increased.\n \n \n Anselmo \n et al. \n (Ref"},{"title":"Addition of 1-Bromopropane; Community Right-to-Know Toxic Chemical Release Reporting","type":"Rule","abstract":"The Environmental Protection Agency (EPA) is adding 1- bromopropane to the list of toxic chemicals subject to reporting under section 313 of the Emergency Planning and Community Right-to-Know Act (EPCRA) of 1986 and section 6607 of the Pollution Prevention Act (PPA) of 1990. 1-Bromopropane has been classified by the National Toxicology Program in their 13th Report on Carcinogens as \"reasonably anticipated to be a human carcinogen.\" The EPA has determined that 1-bromopropane meets the EPCRA section 313(d)(2)(B) criteria because it can reasonably be anticipated to cause cancer in humans.","document_number":"2015-29799","html_url":"https://www.federalregister.gov/documents/2015/11/23/2015-29799/addition-of-1-bromopropane-community-right-to-know-toxic-chemical-release-reporting","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2015-11-23/pdf/2015-29799.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2015-29799.pdf?1448027204","publication_date":"2015-11-23","agencies":[{"raw_name":"ENVIRONMENTAL PROTECTION AGENCY","name":"Environmental Protection Agency","id":145,"url":"https://www.federalregister.gov/agencies/environmental-protection-agency","json_url":"https://www.federalregister.gov/api/v1/agencies/145","parent_id":null,"slug":"environmental-protection-agency"}],"excerpts":"ultimately form a tumor.\n \n Although no studies were identified that were specifically designed to investigate possible modes of action for 1-bromopropane-induced carcinogenesis, the available data indicate that metabolic activation, genetic damage, and oxidative stress from <span class=\"match\">glutathione</span> depletion are important factors. As discussed in the previous section, these factors were linked to several of the primary non-neoplastic toxic effects of 1-bromopropane, including immunosuppression, neurotoxicity, reproductive toxicity, and hepatotoxicity. Other factors"},{"title":"Occupational Exposure to Beryllium","type":"Rule","abstract":"The Occupational Safety and Health Administration (OSHA) is amending its existing standards for occupational exposure to beryllium and beryllium compounds. OSHA has determined that employees exposed to beryllium at the previous permissible exposure limits face a significant risk of material impairment to their health. The evidence in the record for this rulemaking indicates that workers exposed to beryllium are at increased risk of developing chronic beryllium disease and lung cancer. This final rule establishes new permissible exposure limits of 0.2 micrograms of beryllium per cubic meter of air (0.2 [mu]g/m\\3\\) as an 8-hour time-weighted average and 2.0 [mu]g/m\\3\\ as a short-term exposure limit determined over a sampling period of 15 minutes. It also includes other provisions to protect employees, such as requirements for exposure assessment, methods for controlling exposure, respiratory protection, personal protective clothing and equipment, housekeeping, medical surveillance, hazard communication, and recordkeeping. OSHA is issuing three separate standards--for general industry, for shipyards, and for construction--in order to tailor requirements to the circumstances found in these sectors.","document_number":"2016-30409","html_url":"https://www.federalregister.gov/documents/2017/01/09/2016-30409/occupational-exposure-to-beryllium","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2017-01-09/pdf/2016-30409.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2016-30409.pdf?1483710330","publication_date":"2017-01-09","agencies":[{"raw_name":"DEPARTMENT OF LABOR","name":"Labor Department","id":271,"url":"https://www.federalregister.gov/agencies/labor-department","json_url":"https://www.federalregister.gov/api/v1/agencies/271","parent_id":null,"slug":"labor-department"},{"raw_name":"Occupational Safety and Health Administration","name":"Occupational Safety and Health Administration","id":386,"url":"https://www.federalregister.gov/agencies/occupational-safety-and-health-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/386","parent_id":271,"slug":"occupational-safety-and-health-administration"}],"excerpts":"of beryllium sensitization and CBD (NAS, 2008, Document ID 1355). These include TGF-β (Gaede \n et al., \n 2005, Document ID 0486), angiotensin-1 converting enzyme (ACE) (Newman \n et al., \n 1992, Document ID 1440; Maier \n et al., \n 1999 (1458)) and an enzyme involved in <span class=\"match\">glutathione</span> synthesis (glutamate cysteine ligase) (Bekris \n et al., \n 2006, as cited in Document ID 1355). McCanlies \n et al. \n (2010) evaluated the association between polymorphisms in a select group of interleukin genes (IL-1A; IL-1B, IL-1RN, IL-2, IL-9, IL-9R) due to their role"},{"title":"Addition of 1-Bromopropane; Community Right-To-Know Toxic Chemical Release Reporting","type":"Proposed Rule","abstract":"The Environmental Protection Agency (EPA) is proposing to add 1-bromopropane to the list of toxic chemicals subject to reporting under section 313 of the Emergency Planning and Community Right-to-Know Act (EPCRA) of 1986 and section 6607 of the Pollution Prevention Act (PPA) of 1990. 1-Bromopropane has been classified by the National Toxicology Program in their 13th Report on Carcinogens as \"reasonably anticipated to be a human carcinogen.\" EPA believes that 1- bromopropane meets the EPCRA section 313(d)(2)(B) criteria because it can reasonably be anticipated to cause cancer in humans. Based on a review of the available production and use information, 1-bromopropane is expected to be manufactured, processed, or otherwise used in quantities that would exceed the EPCRA section 313 reporting thresholds.","document_number":"2015-08664","html_url":"https://www.federalregister.gov/documents/2015/04/15/2015-08664/addition-of-1-bromopropane-community-right-to-know-toxic-chemical-release-reporting","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2015-04-15/pdf/2015-08664.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2015-08664.pdf?1429015591","publication_date":"2015-04-15","agencies":[{"raw_name":"ENVIRONMENTAL PROTECTION AGENCY","name":"Environmental Protection Agency","id":145,"url":"https://www.federalregister.gov/agencies/environmental-protection-agency","json_url":"https://www.federalregister.gov/api/v1/agencies/145","parent_id":null,"slug":"environmental-protection-agency"}],"excerpts":"that exceed the <span class=\"match\">glutathione</span>-conjugating capacity or may inhibit enzymes required for <span class=\"match\">glutathione</span> synthesis. Because <span class=\"match\">glutathione</span> is an important cellular defense mechanism, reduced levels can lead to oxidative stress, increased toxicity, and carcinogenicity. Numerous studies have shown that 1-bromopropane induces both oxidative stress and <span class=\"match\">glutathione</span> depletion (Lee \n et al. \n 2005, 2007, 2010a, Liu \n et al. \n 2009, 2010, Huang \n et al. \n 2011). Studies with Cyp2e1\n -/- \n knockout mice, cytochrome P450 inhibitors, or a <span class=\"match\">glutathione</span> synthesis inhibitor"}]}